Status and phase
Conditions
Treatments
About
QRX-3, a new drug that stabilized the kidney renal tubular cell and increase the activity of NAD within the kidney cells, is expected to improve baseline renal function when given over a period of one year . The result of the change in renal function will be compared to control without the medication during that same period .
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
127 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal